Pulmocide Raises £17M in Series A Funding

Pulmocide Ltd, a London, UK-based company that develops a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract, raised £17m in Series A funding.

Backers included Imperial Innovations Group plc (AIM: IVO), which is investing £4.25m, SV Life Sciences, Fidelity Biosciences and Johnson & Johnson Development Corporation (JJDC).

Led by Garth Rapeport (CEO) and Pete Strong (CSO), the company will be based at the Imperial BioIncubator in London.



Join the discussion